esketamine

Absorption: 48% absorbed following nasal administration.

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Primarily metabolized to noresketamine (active metabolite) in liver by CYP2B6 and CYP3A4 isoenzymes, and to lesser extent by CYP2C9 and CYP2C19 isoenzymes. Primarily excreted in urine (≥78%; <1% as unchanged drug); ≤2% excreted in feces).

Half-Life: 7–12 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
Intranasal	unknown	20–40 min	unknown

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Hypersensitivity to esketamine or ketamine;
Aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial and peripheral arterial vessels) or arteriovenous malformation;
History of intracerebral hemorrhage;
Severe hepatic impairment;
OB: Pregnancy;
Lactation: Lactation.

Use Cautiously in:

History of hypertensive encephalopathy;
Psychosis;
Moderate hepatic impairment;
Rep: Women of reproductive potential;
Pedi: Safety and effectiveness not established in children; may risk of suicide attempt/ideation especially during early treatment or dose adjustment.

Adv. Reactions/Side Effects ⬆ ⬇

CV: ↑BP, tachycardia

Derm: ↑sweating

EENT: nasal irritation, throat irritation

GI: nausea, vomiting, constipation, diarrhea, dry mouth

GU: urinary tract infection

Neuro: anxiety, depersonalization, derealization, dissociative changes, dizziness, dysgeusia, fatigue, headache, hypoesthesia, sedation, vertigo, cognitive impairment, insomnia, loss of consciousness, slurred/slow speech, SUICIDAL THOUGHTS/BEHAVIORS, tremor

Misc: physical dependence, psychological dependence, tolerance

Interactions ⬆ ⬇

Drug-drug:

Concurrent use with psychostimulants, including amphetamines, methylphenidate, or modafanil, or armodafanil, as well as MAO inhibitors may ↑ BP.
Use with opioids or other CNS depressants, including benzodiazepines, non-benzodiazepine sedative/hypnotics, anxiolytics, general anesthetics, muscle relaxants, antipsychotics, and alcohol may cause profound sedation.

Route/Dosage ⬆ ⬇

Treatment-Resistant Depression

(Adults ): Induction phase (Wk 1–4): 56 mg (2 sprays in each nostril) twice weekly; may ↑ dose (after first dose) based on response and tolerability up to 84 mg (3 sprays in each nostril) twice weekly. Maintenance phase (Wk 5–8): 56 mg (2 sprays in each nostril) or 84 mg (3 sprays in each nostril) once weekly. Maintenance phase (Wk 9 and beyond): 56 mg (2 sprays in each nostril) or 84 mg (3 sprays in each nostril) once weekly or every other wk (use least frequent dosing to maintain remission/response).

Depressive Symptoms in Patients With Major Depressive Disorder With Acute Suicidal Ideation or Behavior

(Adults ): 84 mg (3 sprays in each nostril) twice weekly for 4 wk; may ↓ dosage to 56 mg (2 sprays in each nostril) twice weekly based on tolerability. Reevaluate patient for continued need for treatment after 4 wk.

Availability ⬆ ⬇

Nasal spray: 28 mg/device (14 mg/spray)

Assessment ⬆ ⬇

Monitor patient for sedation for at least 2 hr after each dose.
Monitor BP before and 40 min after administration and periodically during 2 hr after administration. If BP elevated before administration, may hold dose. If elevated following dose, continue to monitor patient.
Assess for history of psychosis. May cause dissociative or perceptual changes (distortion of time, space, and illusions), derealization and depersonalization. Monitor for 2 hr after each dose.
Monitor for worsening and emergence of suicidal thoughts and behaviors, especially during initial few mo of drug therapy and at times of dose changes.
Monitor for urinary tract and bladder symptoms during therapy and refer to an appropriate health care professional as clinically warranted.

Implementation ⬆ ⬇

Do not confuse Spravato with Steglatro.
Must be administered under the supervision of a health care professional.
Due to risks of serious adverse outcomes from sedation, dissociation, and abuse and misuse, available only through a restricted program under Spravato REMS. Health care settings and pharmacies must be certified and patients must be enrolled in REMS program. Esketamine is only administered in health care settings under direct observation of health care professional and patients must be monitored for at least 2 hr after administration.
Advise patient to avoid food for at least 2 hr and liquids for 30 min prior to administration.
If nasal corticosteroid or nasal decongestant is administered on a dosing day, administer at least 1 hr before esketamine administration.
Esketamine is given in conjunction with an oral antidepressant.
May cause dissociative or perceptual changes (including distortion of time, space, and illusions), derealization, and depersonalization; carefully assess patients with psychosis before administering esketamine.
Use 2 devices (for a 56-mg dose) or 3 devices (for an 84-mg dose), with a 5-min rest between use of each device. Do not prime device. Advise patient to gently blow nose before first dose. Check that indicator shows 2 or 3 green dots. Instruct patient to recline head back 45°. Have patient insert device into nostril until nose rest is between nostrils. Close opposite nostril. Sniff gently after administering dose. Take device from patient; confirm no green dots. Instruct patient to recline and rest for 5 min between doses; do not blow nose. Repeat for each dose. Discard according to institution guidelines for Schedule III drugs.

Patient/Family Teaching ⬆ ⬇

Explain purpose of esketamine, administration procedure, and Spravato REMS program to patient.
Advise patient to read Medication Guide before starting therapy. If a treatment session is missed and no worsening of depressive symptoms occurs, continue current dosing schedule. If depressive symptoms worsen, may return to previous dosing schedule.
May cause sedation, dissociative symptoms, perception disturbances, dizziness, vertigo, and anxiety. Caution patient to avoid driving or activities requiring alertness until next day after a restful sleep.
Advise patient, family, and caregivers to look for changes in behavior and suicidality, especially during early therapy or dose changes. Notify health care professional immediately if thoughts about suicide or dying, attempts to commit suicide; new or worse depression or anxiety; agitation or restlessness; panic attacks; insomnia; new or worse irritability; aggressiveness; acting on dangerous impulses, mania, or other changes in mood or behavior.
Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to avoid concurrent use of Rx, OTC, and herbal products without consulting health care professional.
Rep: May cause fetal harm. Advise females of reproductive potential to use effective contraception during therapy and to avoid breastfeeding. Notify health care professional promptly if pregnancy is planned or suspected, or if breastfeeding. Inform patients who become pregnant during therapy of pregnancy registry that monitors pregnancy outcomes in women exposed to antidepressants. Enroll patients by contacting the National Pregnancy Registry for Antidepressants at 1-866-961-2388 or online at https://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/antidepressants/.

Evaluation/Desired Outcomes ⬆ ⬇

Decreased severity of depressive symptoms and prolonged time to relapse.

US Brand Names ⬆ ⬇

Contr. Subst. Schedule ⬆ ⬇

Schedule III (C-III)

Code ⬆

NDC Code

50458- Janssen Pharmaceuticals Inc.
- 50458-028- Spravato
  - 50458-028-02- 2 BLISTER PACK in 1 KIT (50458-028-02) > 1 VIAL, SINGLE-USE in 1 BLISTER PACK > .2 mL in 1 VIAL, SINGLE-USE (50458-028-00)

50458- Janssen Pharmaceuticals Inc.
- 50458-028- Spravato
  - 50458-028-03- 3 BLISTER PACK in 1 KIT (50458-028-03) > 1 VIAL, SINGLE-USE in 1 BLISTER PACK > .2 mL in 1 VIAL, SINGLE-USE (50458-028-00)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇